These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38733494)

  • 1. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.
    Fridh AC; Palmborg A; Ta A; Freigofaite D; Warren S; Perdrizet J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2400751. PubMed ID: 39279284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
    Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
    Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH; Bertran M; Litt DJ; Ladhani SN; Miller E
    Lancet Public Health; 2024 Sep; 9(9):e654-e663. PubMed ID: 39153492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
    Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
    Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom.
    Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
    Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
    Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany.
    Huang M; Weaver JP; Elbasha E; Weiss T; Banniettis N; Feemster K; White M; Kelly MS
    Vaccines (Basel); 2024 Sep; 12(9):. PubMed ID: 39340075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Sep; 42(22):126000. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
    Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
    Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.